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An enduring goal of therapeutic immunosup-
pression is to exploit tolerance mechanisms so 
that short-term therapy can provide long-lived 
benefit (Kendal and Waldmann, 2010). The dis-
covery that short pulses of blocking antibodies 
to co-receptors and co-stimulatory molecules 
could initiate the self-sustaining process of in-
fectious transplantation tolerance, and that this 
was dependent on CD4+ regulatory T cells, 
provided  the  impetus  to  harness  regulatory   
T  cells  as  a  therapeutic  strategy  (Qin  et  al., 
1993). Such approaches would benefit from the 
knowledge  of  exactly  which  regulatory  cells   
are responsible, and where and when they act.   
Until now, much has been assumed in the ab-
sence of definitive proof. For example, despite 
the  identification  of  many  CD4+  regulatory   
T  cell  subsets,  including  Foxp3+  T  cells   
(Bennett  et  al.,  2001;  Fontenot  et  al.,  2003; 
Hori  et  al.,  2003),  IL-10–secreting Tr1  cells 
(Levings et al., 2002), TGF-–secreting Th3 
cells (Weiner, 2001), and most recently Foxp3neg 
iT(R)35 cells (Collison et al., 2010), Foxp3+  
T  reg  cells  have  been  championed  over  the   
rest as essential for graft tolerance by largely   
descriptive  data. This  circumstantial  evidence 
typically falls into three categories: (1) the en-
hancement of graft survival by adoptive transfer 
of Foxp3+-enriched but impure (Graca et al., 
2002b) CD25+CD4+ populations (Feng et al., 
2008; Xia et al., 2009); (2) the peripheral induc-
tion of Foxp3+ T reg cells as a result of tolero-
genic protocols (Cobbold et al., 2004; Battaglia 
et al., 2006; Turnquist et al., 2007); and (3) the 
detection of small numbers of Foxp3+ T reg 
cells in tolerated grafts (Lee et al., 2005; Fan   
et al., 2010; Semiletova et al., 2010). However, 
simply demonstrating their presence, regardless 
of how well it is performed, fails to confirm a 
genuine operational role for Foxp3+ T reg cells. 
Achieving that conclusive evidence has been 
hampered by the lack of a natural cell surface 
marker by which Foxp3+ T reg cells can be 
specifically manipulated in vivo. In addition,   
although diphtheria toxin ablation of Foxp3+ 
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A paradigm shift in immunology has been the recent discovery of regulatory T cells (T reg 
cells), of which CD4+Foxp3+ cells are proven as essential to self-tolerance. Using transgenic 
B6.Foxp3hCD2 mice to isolate and ablate Foxp3+ T reg cells with an anti-hCD2 antibody, we 
show for the first time that CD4+Foxp3+ cells are crucial for infectious tolerance induced 
by nonablative anti–T cell antibodies. In tolerant animals, Foxp3+ T reg cells are constantly 
required to suppress effector T cells still capable of causing tissue damage. Tolerated tissue 
contains T cells that are capable of rejecting it, but are prevented from doing so by thera-
peutically induced Foxp3+ T reg cells. Finally, Foxp3+ cells have been confirmed as the 
critical missing link through which infectious tolerance operates in vivo. Peripherally in-
duced Foxp3+ cells sustain tolerance by converting naive T cells into the next generation of 
Foxp3+ cells. Empowering Foxp3+ regulatory T cells in vivo offers a tractable route to avoid 
and correct tissue immunopathology.
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induced Foxp3+ (i)T reg cells to recruit new Foxp3+ T reg 
cells from naive CD4+ cells in vivo provides a long awaited 
explanation for infectious tolerance.
RESULTS
Ablation of Foxp3+ T reg cells in B6.Foxp3hCD2 mice
Except for the knocked-in sequence, B6.Foxp3hCD2 mice are 
genetically identical to WT C57BL/6 (B6) mice, have an 
identical phenotype, and, importantly, do not develop any 
wasting immunopathology indicating normal Foxp3 regu-
latory function (Fig. S1). Analysis of splenic, lymph node, 
and blood compartments reveals similar CD4+, CD8+, and 
CD19+ lymphocyte composition between knock-in and WT 
B6 mice (Fig. S1). The absolute number, as well as the per-
centage, of CD4+ cells that are Foxp3+ is also similar between 
the two strains (Fig. S1, C and D). In B6.Foxp3hCD2 mice, 
the hCD2_CD52 fusion protein appears to be a highly accu-
rate reporter of Foxp3+CD4+ cells (>98% of Foxp3+ cells   
are hCD2+; Fig. S1 B), allowing reliable isolation of live   
Foxp3negative and Foxp3positive T cell populations by flow cytom-
etry and cell sorting.
The high sensitivity of the hCD2_CD52 fusion protein 
for Foxp3 expression also allows targeted ablation of Foxp3+ 
T reg cells by anti–human CD2 (YTH655) rat IgG2b mAb 
(Friend et al., 1987; Qin et al., 1993). A single dose of 1 mg 
of depleting anti-hCD2 mAb removed >95% of circulating 
cells in DEREG models (depletion of regulatory T cells) has 
dramatically demonstrated the importance of Foxp3+ T reg 
cells in self-tolerance, the resultant systemic immunopathol-
ogy is so severe that it limits the investigation of long-term 
induced tolerance to foreign antigen (Kim et al., 2007). Few 
mice survive beyond 3 wk, and any destruction of foreign 
graft tissue within that time period would have to be inter-
preted in the context of global tissue disruption (whether for-
eign or host) by an unregulated immune system (Kim et al., 
2007; Lahl et al., 2007). Using a different approach, in this   
paper we provide the first definitive evidence of an essential 
role for Foxp3+ T reg cells in therapeutic transplant tolerance in 
otherwise healthy mice. We use a transgenic reporter mouse con-
taining a sequence coding for a GPI-linked human CD2_CD52 
fusion protein in the 3UTR of the X-linked foxp3 gene (B6.
Foxp3hCD2) such that all Foxp3-expressing cells coexpress the 
fusion protein on their cell surface (Komatsu et al., 2009).   
Using ablative anti–human CD2 antibodies, we show that 
Foxp3+ T reg cells are necessary for therapeutic tolerance in-
duced  by  co-receptor/co-stimulatory  blockade  across  full 
MHC, multiple minors, and single minor histocompatibility 
barriers. T cells capable of rejecting the tolerated graft remain 
quiescent in a tolerant host as a result of constant suppression 
by Foxp3+ T reg cells. A key site of this suppression turns out 
to be the graft tissue itself, which contains T cells otherwise 
capable  of  rejection.  Finally,  the  ability  of  antigen-specific   
Figure 1.  Ablation of FoxP3+ T cells with an anti–human CD2 antibody. (A) Ablation of Foxp3+ cells after B6.Foxp3hCD2 mice received 1 mg YTH655 
(at anti-hCD2 IgG2b mAb) i.p. in indicated organs. Three mice/group/time point are shown. (B) Foxp3+ cells after seven daily i.p. injections of 250 µg 
YTH655. P < 0.001. Three mice/group/time point are shown. (C) Flow cytometry analysis of spleen, lymph, and blood cells 4 wk after 2–10 million B6.Foxp3hCD2 
splenocytes were injected i.v. into lymphocyte-deficient B6.RAG/ recipients with 1 mg anti-hCD2 (squares; n = 16 composite of four experiments).  
**, P < 0.01 for the ablative effect of antibody compared to controls. (D) Splenocytes from B6.Foxp3hCD2 mice pretreated (open triangles, n = 6) or not  
(open circles, n = 3) with 7 × 250 µg anti-hCD2 mAb (30–40% of Foxp3+ T cells survived) were harvested and transferred into B6 RAG/ mice with 1 mg 
anti-hCD2. P < 0.0001 compared with control (circles, n = 3). In all cases, horizontal bars represent the arithmetic mean and error bars represent SEM.JEM Vol. 208, No. 10 
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critical CD4+ regulatory cells responsible for this suppression. 
B6.Foxp3hCD2 were crossed with CBA/Ca mice to generate 
hybrid offspring known to be susceptible to our tolerance-
inducing protocols (Daley et al., 2007). Because the foxp3 gene 
is X linked, all the Foxp3+ T cells in male (CBAxB6hCD2)F1 
progeny would be susceptible to anti-hCD2 mAb–mediated 
ablation. CBAxB6hCD2 mice are haplotype H-2kxH-2b and 
rapidly rejected skin grafts mismatched by multiple minor anti-
gens from H-2k Balb/K mice (Fig. 2 A). They did, however, 
accept Balb/K skin long term when the grafts were trans-
planted  under  the  cover  of  nondepleting  anti-CD4,  anti-
CD8, and anti-CD40L mAb blockade (P < 0.0001). Once 
therapeutic antibody levels had naturally decayed, a challenge 
Balb/K graft failed to break tolerance to the first graft and was 
itself accepted long term, indicating that tolerance remains 
active and self-sustaining (Fig. 2 A and Fig. S3). Classical 
adoptive transfer studies have previously demonstrated that 
tolerant CD4+ cells, from mice tolerized in this way, can sup-
press both naive and primed lymphocytes when transferred 
into lymphocyte deficient hosts (Marshall et al., 1996). Using 
a similar cell transfer protocol where we could guarantee 
>95% removal of Foxp3+ T cells (Fig. 1, C and D), we revis-
ited these pioneering studies to investigate the exclusive roles 
of Foxp3+ T reg cells. 20 million tolerant splenocytes were 
harvested  from  male  (CBAxB6hCD2)F1  mice  that  had  ac-
cepted a Balb/K graft for over 60 d. These were then trans-
ferred  into  lymphocyte-deficient  RAG/  recipient  mice 
that  were  transplanted  on  the  same  day  with  a  challenge 
Balb/K skin graft. All such grafts were accepted despite   
co-transfer of five million naive splenocytes (Fig. 2 B, tri-
angles) or one million primed splenocytes (Fig. 2 B, circles). 
Foxp3+ T cells in euthymic B6.Foxp3hCD2 mice within 3 d—
at least 10 d before the peak anti-globulin response is de-
tected (Fig. 1 A and Fig. S2). However, between 30 and 40% 
residual Foxp3+ T cells were still detected in the spleen and 
lymph nodes, potentially contributing to the rapid recovery 
of pretreatment Foxp3+ T reg cells levels after 6 d. The use of 
multiple smaller doses of depleting anti-hCD2 mAb (e.g., 7 d 
of 250 µg) improved the degree of Foxp3+ T cell ablation in 
splenic and lymph compartments and further delayed T reg 
cell recovery until at least 25 d after the first dose (Fig. 1 B). 
Our finding that circulating Foxp3+ T cells were more sus-
ceptible to ablation than those resident in lymphoid tissue   
allowed us to exploit adoptive cell transfer protocols to de-
plete intravenously infused circulating cells. When spleno-
cytes from B6.Foxp3hCD2 mice were intravenously injected 
into lymphocyte-deficient (RAG/) recipients, 1 mg anti-
hCD2 mAb i.p./i.v. proved far more ablative, with <2% of 
residual Foxp3+ T reg cells detectable in splenic, lymphatic, 
and blood compartments of recipient RAG/ mice 4 wk later 
(Fig. 1 C). Even Foxp3+ splenocytes from B6.Foxp3hCD2 re-
porter mice that appeared refractory to the initial round of 
systemic depletion were efficiently ablated on subsequent adop-
tive transfer in the presence of anti-hCD2 mAb (Fig. 1 D).
Adoptive transfer of tolerance requires Foxp3+ T reg cells
It  has  long  been  known  that  short-term  co-receptor/co-
stimulatory blockade can induce long-term tolerance to for-
eign tissue and that regulatory elements within the CD4+ 
population carry that tolerance with them when adoptively 
transferred into secondary hosts (Scully et al., 1994). We in-
vestigated whether Foxp3+ T reg cells, in particular, were the 
Figure 2.  Loss of transplant tolerance and suppression 
on adoptive transfer after ablation of FoxP3+ T cells.  
(A) (CBAxB6hCD2)F1 mice can be made tolerant to multiple 
minor mismatched Balb/K skin grafts with anti-CD4/CD8/
CD40L blocking mAb (squares, n = 23; P < 0.0001 compared 
with control; circles, n = 4). The skin grafts were accepted for 
>150 d and were not rejected despite challenge grafting at 
day 60 (arrow). (B) Tolerant spleen cells were harvested from 
another cohort of (CBAxB6hCD2)F1 mice that had accepted a 
Balb/K graft for at least 60 d and transferred into RAG/ 
recipients in conjunction with a challenge Balb/K graft.  
20 million tolerant splenocytes from male (CBAxB6hCD2)F1 mice 
suppressed the addition of five million naive splenocytes 
(triangles, n = 6) and one million primed splenocytes (circles, 
n = 5). This suppression was dependent on Foxp3+ T cells 
because anti-hCD2 mAb led to rapid rejection of the skin 
grafts. P = 0.0026 (n = 9) and P = 0.0168 (n = 5), respectively 
(one mouse in each group was euthanized). (C) 20 million 
tolerant splenocytes from male (CBAxB6hCD2)F1 mice that 
accepted the first Balb/K graft also accepted a Balb/K skin 
graft when adoptively transferred into lymphocyte de-
plete (RAG/) recipients. When 1 mg anti-hCD2 was co- 
administered, the grafts were rejected. P = 0.0008 (n = 11). (D) 20 million tolerant splenocytes from female (CBAxB6hCD2)F1 mice that accepted the first 
Balb/K graft also accepted a Balb/K skin graft when adoptively transferred into lymphocyte deplete (RAG/) recipients with (open triangles, n = 8) or 
without (closed triangles, n = 3) anti-hCD2 mAb. In the same experiment, 20 million tolerant splenocytes from male (CBAxB6hCD2)F1 mice rejected the 
second Balb/K graft when co-administered with anti-hCD2 mAb (circles, n = 4; P = 0.0047 one mouse was euthanized).2046 Foxp3+ T reg cells in infectious tolerance | Kendal et al.
within tolerant hosts and are constantly kept in check by 
Foxp3+ T reg cells.
A major limitation of cell transfer studies, such as those in 
the previous paragraph, is that homeostatic expansion may ar-
tificially  magnify  the  potency  of  an  otherwise  insignificant 
population of effector T cells. In addition, adoptive transfer of 
lymphocytes in the presence of anti-hCD2 mAb led to such 
efficient ablation of Foxp3+ cells (Fig. 1, C and D) that the re-
cipient mice developed immunopathology within 4 wk and 
three mice had to be euthanized (Fig. 2, B and D). In compari-
son, mice treated systemically with anti-hCD2 mAb, which 
spares up to a third of splenic Foxp3+ cells (Fig. 1, A and B), do 
not exhibit signs of disease, remain well, and gain weight for 
>150 d. For these reasons, we investigated whether residual 
effector function could also be revealed when Foxp3+ T reg 
cells were ablated in the more physiologically relevant model 
of a healthy naive mouse with a replete immune system.
CBAxB6hCD2 (H-2kxH-2b) accepted MHC mismatched 
skin grafts from Balb/C (H-2d) mice long term when those 
grafts  were  transplanted  under  the  cover  of  nondepleting 
anti-CD4, anti-CD8, and anti-CD40L mAb blockade (Fig. 3 A; 
P < 0.0001). Once therapeutic antibody levels had naturally 
decayed, the mice were able to accept second donor chal-
lenge grafts long term. In this stringent MHC mismatched 
graft model, we could again show that Foxp3+ T reg cells 
were necessary for long-term graft survival as ablative anti-
hCD2 mAb therapy resulted in prompt rejection of second-
ary challenge grafts compared with control mice (Fig. 3 B; 
MST 12 vs. 47 d of isotype control mAb; P < 0.0001). More-
over, we observed that the original tolerated graft was also 
rejected, despite appearing well healed for >100 d (Fig. 3 C; 
MST [+100d] 17 vs. 38 d of isotype control; P = 0.0012). 
Rejection of the original tolerizing grafts did not 
require  any  inflammatory  antigenic  stimulus 
from a second challenge graft because treatment 
with anti-hCD2 mAb alone 50 d after tolerance 
induction  again  resulted  in  prompt  rejection 
(Fig. 3 D; MST 16, P < 0.0001). That rejection 
Suppression by tolerant cells was abrogated by injecting the 
ablative anti-hCD2 mAb to target Foxp3+ T reg cells (Fig. 2 B, 
open triangles [P = 0.0026] and open circles [P = 0.0168]). 
This demonstrated unequivocally, and for the first time, that 
Foxp3+ T reg cells are essential for the suppression found in 
therapeutic transplant tolerance.
Foxp3+ T reg cells constantly suppress effector T cells  
in a tolerant host
Remarkably, mice that received just the 20 million tolerant 
splenocytes with ablative anti-hCD2 mAb also rapidly re-
jected the Balb/K graft in comparison with control mice 
(Fig. 2 C, open vs. closed squares; P = 0.0008), albeit at a 
slower rate than when naive cells were co-transferred (Fig. 2, 
B and C; median survival time [MST] = 23 vs. 14 d, respec-
tively; P = 0.0019). Importantly, anti-hCD2 mAb ablation of 
female (CBAxB6hCD2)F1 splenocytes (in which only approxi-
mately half of all Foxp3+ cells would be hCD2+ through ran-
dom X inactivation) failed to result in graft rejection compared 
with male positive controls (Fig. 2 D; P = 0.0047). The find-
ing that a tolerant population, when stripped of its Foxp3+  
T reg cells, could nonetheless reject grafts demonstrated that 
rejection-competent T cells were still present despite the state 
of operational tolerance. This challenges preconceptions that 
regulatory cells are at their most active during tolerance in-
duction by rendering any potential rejecting T effector cells 
anergic (Alters et al., 1991; Wekerle et al., 2002). It is also 
consistent with our previous findings that CD8+ cells from 
primed, yet tolerized, hosts retained the ability to reject for-
eign grafts once all CD4+ cells (including regulators) were 
removed (Marshall et al., 1996). Collectively, these experi-
ments suggest that T cells fully capable of rejection remain 
Figure 3.  Loss of transplant tolerance after ablation 
of Foxp3+ T cells in tolerant hosts. (A) Male 
(CBAxB6hCD2)F1 mice treated with anti-CD4/CD8/CD40L 
blocking mAb (3 × 3 mg doses over 7 d) accepted an MHC 
mismatched Balb/C skin (n = 27; P < 0.0001). (B) After 100 d, 
a challenge Balb/C skin graft was transplanted. Mice that 
received ablative anti-hCD2 mAb to deplete Foxp3+ T cells 
(squares, n = 16) rapidly rejected the challenge graft. MST 
12.0 versus 47.0 d of control group (circles, n = 11), P < 
0.0001. (C) The original tolerizing Balb/C graft was also 
rapidly rejected when mice received anti-hCD2 mAb 
(squares, n = 16). MST (+100d) 17.5 versus 38.0 d of con-
trol group (circles, n = 11), P = 0.0012. (D) Even without a 
challenge graft, mice that received anti-hCD2 mAb to ab-
late Foxp3+ T cells (downward triangles, n = 4; squares,  
n = 9) rejected a Balb/C graft that had been well tolerated 
for 50 d, with (P = 0.045) or without (P < 0.0001) a  
co-transplanted syngeneic graft.JEM Vol. 208, No. 10 
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were  backcrossed  onto  transgenic  RAG/ 
Marilyn mice to generate RAG/ Marilyn.
Foxp3hCD2 female mice containing only mono-
clonal  CD4+  lymphocytes  recognizing  the 
male Dby peptide. Because these mice do not 
have any natural thymic-derived T reg cells, any detectable 
Foxp3+ cells will be induced (iT reg cells), should express cell 
surface hCD2, and consequently should be susceptible to ab-
lation  by  anti-hCD2  mAb.  As  expected,  female  RAG/ 
Marilyn.Foxp3hCD2 recipients rejected male B6 RAG/ skin 
grafts but could be made tolerant by short-term treatment 
with anti-CD4 blocking mAb (Fig. 4 A; P = 0.0001). This 
induced tolerance was associated with the appearance of 
hCD2+Foxp3+ iT reg cells in the periphery, whereas no 
hCD2+Foxp3+ T reg cells were found in untreated female 
RAG/ Marilyn.Foxp3hCD2 that had rejected the male graft 
(Fig. 4 B). As previously discussed, such correlative data does 
not prove a necessary role for hCD2+Foxp3+ iT reg cells in 
therapeutic tolerance. Their presence could, for example, be a 
bystander consequence and not the driving force of tolerance 
induction.  Past  work  has  shown  that  TGF-–conditioned 
CD4+ T cells could suppress graft rejection in vivo (Cobbold 
et al., 2004), but because such populations are mixtures of 
can occur without reexposing the immune system to antigen 
under inflammatory conditions (i.e., challenge grafting) or an 
inflammatory insult from a syngeneic graft (Fig. 3 D) demon-
strates the existence of a residual population of effector   
T cells that remain capable of rejecting a graft were it not for 
their continuous restraint by Foxp3+ T reg cells. These results 
indicate that short-term antibody-mediated immune blockade 
achieves  long-term  tolerance  through  promoting  constant 
immune vigilance by Foxp3+ T reg cells, not simply by inca-
pacitating effector T cells at the outset.
De novo–induced Foxp3+ (i)T reg cells can also  
suppress rejection
Having shown that Foxp3+ T reg cells are critical to therapeu-
tic transplant tolerance in conventional mice, we next used a 
single TCR transgenic Foxp3 reporter model to investigate 
the role, if any, of antigen-specific peripherally induced Foxp3+ 
T reg cells (iT reg cells). The original B6.Foxp3hCD2 mice 
Figure 4.  Foxp3+ iTreg cells are induced in vivo 
by co-receptor blockade, and FoxP3+ iTreg cells 
induced by TGF in vitro are suppressive in vivo.  
(A) Female transgenic RAG/ Marilyn.Foxp3hCD2 mice 
can be tolerized to male B6 RAG/ skin by anti-CD4 
blocking mAb (squares, n = 10; P = 0.0001). (B) De novo 
hCD2+Foxp3+ T reg cells were found in the spleen, 
draining, and mesenteric lymph nodes, but not the 
thymus, of Marilyn.Foxp3hCD2 mice that accepted a 
male graft for at least 60 d but not in untreated  
rejecting RAG/ Marilyn.Foxp3hCD2 mice (P < 0.0001). 
(C) 5 × 105 TGF-–conditioned male H-Y antigen-specific 
hCD2+ CD4+ RAG/ Marilyn.Foxp3hCD2 (DBYT) cells 
failed to reject a male CBA.Ca RAG/ graft (circles,  
n = 7) when injected into B6 RAG/ recipients com-
pared with 5 × 105 hCD2 DBYT cells (open squares,  
n = 11; P = 0.0003) or 1 × 105 naive CD4+ RAG/ Mari-
lyn.Foxp3hCD2 cells (open triangles, n = 6; P = 0.0006). 
The hCD2 DBYT group consists of mice injected with 
MoFlow-sorted hCD2 DBYT cells. Alone, n = 3; plus 
anti-hCD2 mAb, n = 4; plus isotype control mAb, n = 4. 
(D) 5 × 105 unsorted (DBYT) cells (squares, n = 4) and  
5 × 105 hCD2+ cells (diamond, n = 5) fail to reject a male 
CBA.Ca RAG/ graft when injected into B6 RAG/ 
recipients. Elimination of hCD2+Foxp3+ T cells, either by 
anti-hCD2 mAb (open squares, n = 5; P = 0.0095) or 
MoFlow cell sorting of hCD2 cells (open triangles,  
n = 5; P = 0.0039), results in graft rejection. A challenge 
graft co-transplanted with 1 × 105 naive RAG/ Mari-
lynWT CD4+ cells after 30 d (arrow) fails to break toler-
ance and is itself accepted long term. (E) A positive 
control group is included to demonstrate that 1 × 105 
naive RAG/ MarilynWT CD4+ cells normally reject male 
skin when injected into naive RAG/ mice (open cir-
cles, n = 3; P = 0.0062). **, P < 0.01; ***, P < 0.001.2048 Foxp3+ T reg cells in infectious tolerance | Kendal et al.
retransplanted onto a female lymphocyte-deficient host. This 
process ensured that any functional T cells in the new host 
(whether effector or regulator) would be from the original   
female RAG/ Marilyn.Foxp3hCD2 mice and could only have 
been transferred within the graft tissue itself (Fig. 5). Remark-
ably, injection of ablative hCD2 antibody into recipient mice 
resulted in significant rejection of these previously tolerated 
grafts compared with control mice (Fig. 5; P = 0.0040).   
Collectively, these data establish several key findings. First,   
de novo antigen-specific Foxp3+ iT reg cells are produced in 
the periphery during tolerance induction through co-receptor 
blockade. Second, these peripheral Foxp3+ iT reg cells are sup-
pressive and prevent potential effectors from rejecting grafts. 
Third, because the tolerated graft tissue itself contains CD4+ 
effector T cells fully capable of rejection, its survival depends on 
constant suppression by Foxp3+ iT reg cells generated de novo 
in response to the tolerizing protocol.
Infectious tolerance requires and generates Foxp3+ T reg cells
Infectious transplant tolerance describes a self-sustaining pro-
cess by which a population of tolerant immune cells can pass 
on that tolerance to naive cells (Qin et al., 1993). We investi-
gated whether antigen-specific Foxp3+ (i)T reg cells were the 
secondary cohort of T cells generated by infectious tolerance. 
This required reliable distinction between the original toler-
ant population and the naive population that might be con-
verted, as well as the absence of Foxp3+ cells in the naive 
population at the outset of the experiment. In vitro–generated 
TGF-–induced hCD2+CD4+ antigen-specific Foxp3+ (i) T reg 
cells were isolated (Fig. S4) and infused into lymphocyte- 
deficient female B6.RAG/ recipient mice (Fig. 6). A sec-
ond group received naive CD4+ cells from RAG/ MarilynWT 
mice that lacked natural Foxp3+ T reg cells. The third group 
received a mixture of 5:1 hCD2+CD4+ cells and naive CD4+ 
cells. All groups received a male CBA.RAG/ skin graft after 
24 h. None of the mice that received hCD2+ cells rejected 
their male grafts. In comparison, all the mice receiving naive 
Foxp3+ and Foxp3 T cells it has not yet been established 
which are the active components. To investigate whether 
Foxp3+ iT reg cells are the suppressive agents, we derived   
antigen-specific Foxp3+ iT reg cells from RAG/ Marilyn.
Foxp3hCD2 splenocytes cultured in vitro with dendritic cells, 
TGF-, and the cognate Dby peptide for 7 d (DBYT cells; 
Fig. S4). Female RAG/ mice that received either unsorted 
DBYT cells or purified hCD2+Foxp3+ T reg cells accepted a 
male graft and exhibited dominant tolerance by resisting a 
later challenge graft given together with 1 × 105 monoclonal 
naive T cells (Fig. 4, D and E), a cell number at least 10-fold 
in excess of the minimum required to reject male skin (un-
published data). In comparison, female RAG/ mice that re-
ceived MoFlow-sorted hCD2negative cells, devoid of Foxp3+  
T reg cells, rejected the male RAG/ grafts (Fig. 4 C;   
P = 0.0003). The hCD2 group (Fig. 4 C, squares) initially 
included  four  mice  that  received  hCD2  MoFlow-sorted 
DBYT cells combined with further ablative anti-hCD2 to 
ensure that removal of Foxp3+ cells was optimized. In retro-
spect, cell sorting of hCD2 cells alone turned out to be suffi-
cient to expose rejection, and this precautionary maneuver 
was not performed in subsequent assays (Fig. 4, C and D).
Tolerated grafts harbor rejecting T cells
We have previously shown that T cells found in tolerated 
skin can recolonize a lymphocyte-deficient mouse and sup-
press graft rejection (Graca et al., 2002a). We have also shown 
that tolerated grafts are enriched with peripherally induced 
Foxp3+  iT  reg  cells  in  RAG/  TCR  transgenic  mice   
(Cobbold et al., 2004). Indeed, CD25+ cells within grafts ac-
cepted  by  RAG/  TCR  transgenic  tolerance  can  carry   
tolerance over to naive lymphocyte deficient mice. In com-
parison, spleens cells from tolerant RAG/ TCR transgenic 
mice were still able to reject the same donor skin on adoptive 
transfer (Cobbold et al., 2006). Consistent with these early 
findings, lymphocytes harvested from the whole animal, but 
not the graft, of anti-CD4–treated female RAG/ Marilyn.
Foxp3hCD2 that had accepted a male graft long term rejected 
a  subsequent  male  graft  when  adoptively  transferred  into   
female B6.RAG/ mice (Fig. S5). Ablation of Foxp3+ T reg 
cells with anti-hCD2 mAb did result in significant increase in 
the rate of graft rejection, revealing a regulatory, albeit mini-
mal, role for these cells at the whole animal level (Fig. S5;   
P = 0.0313). Collectively, it seems that, compared with con-
ventional mice, transferable regulation in TCR transgenic 
mice is best seen within accepted grafts, making graft transfers 
a useful model to investigate the role of Foxp3+ iT reg cells 
in tissue specific transplantation tolerance.
By adapting a two-step transplantation study, we now ask 
whether specifically Foxp3+ iT reg cells in the graft tissue are 
innocent bystanders or contributing to tolerance by protecting 
the tissue from infiltrating effector cells. Lymphocyte-deficient 
male  B6  RAG/  skin  grafts  were  first  placed  on  female 
RAG/ Marilyn.Foxp3hCD2 mice and tolerance was induced 
through short-term anti-CD4 mAb blockade (Fig. 4 A). After 
2 mo, the well tolerated male skin graft was then immediately 
Figure 5.  FoxP3+ T cells within grafted tissue contributed to the 
survival of tolerated skin grafts transferred onto lymphopenic  
recipients. Male B6 RAG/ grafts that were tolerated by anti-CD4  
mAb–treated female RAG/ Marilyn.Foxp3hCD2 mice (Fig. 4 A) were then 
retransplanted onto lymphocyte-deficient female B6 RAG/ recipients. 
Ablation with anti-hCD2 mAb (squares, n = 11) resulted in rapid graft 
rejection compared with isotype control mAb (circles, n = 10; P = 0.0040).JEM Vol. 208, No. 10 
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DISCUSSION
Foxp3+ T reg cells are known to be essential for self-tolerance 
with a severe wasting immunopathology developing in their 
absence (Kim et al., 2007). Similarly, they are necessary in 
certain mouse models that can naturally accept foreign tissue 
without the need for additional immunosuppression (Benghiat 
et al., 2005; Robertson et al., 2007; Miyajima et al., 2011). 
We have now, for the first time, been able to demonstrate that 
Foxp3+ cells are also critical to long-term therapeutic toler-
ance to foreign antigen induced by clinically relevant proto-
cols  of  antibody-mediated  co-receptor  and  co-stimulatory 
blockade. Foxp3+ T reg cells are required for tolerance induc-
tion across all three levels of histocompatibility mismatch: full 
MHC, multiple minor, and single minor antigen.
Adoptive transfer of spleen cells from tolerant mice into 
naive lymphocyte-deficient recipients demonstrated that once 
tolerance is established, Foxp3+ T reg cells maintain that state 
despite challenges from naive and primed lymphocytes (Fig. 2). 
A recent study has demonstrated that nonspecific cell lysis   
may release extracellular factors (e.g., NAD+) that could them-
selves override suppression (Scheuplein et al., 2009). Given that 
all  adoptively  transferred  Foxp3+hCD2+  cells  from  male 
(CBAxB6hCD2)F1 mice were susceptible to ablation by anti-
hCD2 mAb, it was conceivable that the resulting cell destruc-
tion was a major contributor to the loss of tolerance, independent 
of specifically targeting Foxp3+ cells. To exclude this, spleen 
RAG/ MarilynWT CD4+ cells (alone) rejected their grafts 
(Fig. 6 A; P = 0.0066). Half of the mice that received a mix-
ture of hCD2+ cells (iT reg cells) and naive CD4+ cells re-
jected the male graft (Fig. 6 A; P = 0.0247). Those mice that 
accepted the male skin for >100 d were analyzed for Foxp3+ 
expression. Although the total splenic white cell count was 
similar in all three groups, there were more CD4+ cells in   
the group that received a mixture of tolerant + naive cells 
(Fig. 6 B). Very few, if any, Foxp3+ cells were found in mice 
that had received 100,000 naive CD4+ cells alone and re-
jected the male skin. In contrast, Foxp3+ cells were found in 
the spleen and draining lymph nodes of mice that had accepted 
the male graft for >100 d (Fig. 6 C). In those mice that re-
ceived a 5:1 mixture of hCD2+/naive CD4+ cells, 18% of 
Foxp3+ cells in draining lymph nodes and 24% in the spleen 
were hCD2 negative, whereas <2% of Foxp3+ cells in mice 
that received hCD2+ cells alone were hCD2neg (Fig. 6 C;   
P = 0.0009). The presence of hCD2negFoxp3+ cells in only 
those mice that received the 5:1 mixture demonstrated that 
some of the naive CD4+ cells from RAG/ MarilynWT mice 
developed into Foxp3+ T reg cells as a result of coexistence 
with tolerant hCD2+ cells from RAG/ Marilyn.Foxp3hCD2 
mice. This finding that Foxp3+ T reg cells not only suppress 
but also facilitate conversion of naive T cells into new Foxp3+ 
(i)T reg cells provides one mechanism by which infectious 
tolerance may occur in vivo.
Figure 6.  In vitro–generated Foxp3+ 
iTreg cells prevented graft rejection by 
naive CD4 T cells and allowed some naive 
T cells to become Foxp3+ themselves. Female 
B6.RAG/ received a male CBA.RAG/ skin 
graft in conjunction with either 5 × 105 in 
vitro–cultured female hCD2+ RAG/ Marilyn.
Foxp3hCD2 DBYT cells (squares, n = 6), 1 × 105 
naive CD4+ cells from RAG/ MarilynWT  
mice (circles, n = 6), or a mixture of both  
(diamonds, n = 8). (A) All of the mice that 
received 1 × 105 naive CD4+ cells rejected the 
male skin compared with none of those that 
received 5 × 105 hCD2+ cells (P = 0.0066) and 
half that received a mixture (P = 0.0247). 
After 100 d, the mice were killed and Foxp3+ 
cell composition was analyzed. (B) Total white 
cell spleen counts were similar between the 
three groups, but there were more CD4+ cells 
in mice that received a mixture of hCD2+ and 
naive CD4+ cells. (C) FACS analysis demon-
strated conversion of naive CD4+ cells into 
Foxp3+ T cells. Over 98% of Foxp3+ cells in 
mice that received 5 × 105 isolated hCD2+ 
RAG/ Marilyn.Foxp3hCD2 cells alone were 
hCD2+, whereas 18% of Foxp3+ cells in the 
draining lymph and 24% in the spleen of mice 
that received a 5:1 mixture (and had  
accepted the male graft) were hCD2 negative 
(P = 0.0009). Error bars represent SEM.2050 Foxp3+ T reg cells in infectious tolerance | Kendal et al.
to be active participants in transplant tolerance and not merely 
coincidental bystanders because purified (hCD2 sorted) 
Foxp3, but not (hCD2+ sorted) Foxp3+, cell populations   
resulted in male graft rejection when transferred into lym-
phocyte-deficient hosts (Fig. 4, C–E). Finally, male B6 
RAG/ skin grafts, which had been well tolerated by female 
RAG/ Marilyn.Foxp3hCD2 for >60 d, were surgically re-
moved and immediately retransplanted onto the flank of fresh 
lymphocyte-deficient female B6 RAG/ mice. This process 
ensured that any functional T cells in the new host (whether ef-
fector or regulator) would be from the original female RAG/ 
Marilyn.Foxp3hCD2 mice and could only have been transferred 
within the graft tissue itself (Fig. 5). Ablation of Foxp3+ T reg 
cells resulted in rejection of the graft, demonstrating that a fully 
tolerated graft can still harbor T cells capable of causing its own 
rejection. Graft acceptance therefore requires constant suppres-
sion of these potential rejecter cells by resident Foxp3+ iT reg 
cells—originally generated by the tolerizing protocol.
Several studies have previously shown de novo induction 
of Foxp3+ iT reg cells in response to tolerogenic conditions, 
but their active role in maintaining a state of transplant toler-
ance has not been established (Cobbold et al., 2004; Ochando 
et al., 2006; Fan et al., 2010; Farquhar et al., 2010). Our gen-
eration and subsequent ablation of Foxp3+ (i)T reg cells in 
TCR transgenic RAG/ Marilyn.Foxp3hCD2 mice is the first 
direct evidence that peripherally generated new Foxp3+  
(i)T reg cells are genuinely involved in therapeutic tolerance 
(Figs. 4 and 5). Furthermore, once Foxp3+ (i)T reg cells are 
induced, they maintain their numbers through the conversion 
of naive CD4+ cells into new Foxp3+ cells—i.e., infectious 
tolerance (Fig. 6). Early transplant studies explored the condi-
tions required for infectious tolerance (Qin et al., 1993; Graca 
et al., 2000; Cobbold et al., 2009), whereas in vitro assays sug-
gested a role for Foxp3+ (i)T reg cells (Jonuleit et al., 2002; 
Chen et al., 2003; Andersson et al., 2008). We have been able 
to build on these to demonstrate in vivo that infectious toler-
ance both requires and generates Foxp3+ cells. The necessity 
for persistent antigenic stimuli to maintain the new Foxp3+ 
converts has been suggested in previous studies in which toler-
ance is lost when the accepted graft is removed prematurely 
(Scully et al., 1994; Marshall et al., 1996). Consistent with this, 
very few new Foxp3+ converts from the naive CD4+ popula-
tion were seen in those RAG/ mice that rejected their male 
graft despite co-transfer of hCD2+ iT reg cells (Fig. S6). Col-
lectively, these findings demonstrate that short-term immune 
blockade initiates the generation of new Foxp3+ cells that there-
after maintain transplant tolerance through self-replenishment.
Our  findings  support  the  emerging  importance  of  the   
local tissue microenvironment in determining the degree of 
immune regulation within a tissue. At extremes, such tissue- 
dependent regulation can manifest as sites of immune privilege, 
such as the eye, which accept grafts without additional immuno-
suppression.  Indeed,  local  tolerance  of  alloantigen  injected 
into the anterior chamber of the eye can spread beyond the 
local environment to influence systemic tolerance, the so-called 
anterior chamber–associated immune deviation (Streilein, 2003). 
cells from tolerant female (CBAxB6hCD2)F1 mice were adop-
tively transferred into lymphocyte-deficient hosts, with and 
without  anti-hCD2  mAb.  Because  both  the  natural  and 
knocked in foxp3 gene are X linked, female (CBAxB6hCD2)F1 
mice would inherit both copies and random X inactivation 
would ensure that approximately half the Foxp3+ cells would 
be hCD2+, and so lysed by anti-hCD2 antibody, whereas the 
rest would express the WT foxp3 gene and survive (Fig. 2 D). 
The failure of tolerant female (CBAxB6hCD2)F1 spleen cells 
plus ablative anti-hCD2 to reject any grafts demonstrated that 
cell lysis alone was unlikely to contribute significantly to the 
abrogation of tolerance in this model.
A surprising finding was that even a population of tolerant 
cells, without the addition of naive or primed cells, could still 
reject a graft if stripped of its Foxp3+ T reg cells (Fig. 2 D). This 
implied, first, that tolerance induction fails to incapacitate all 
cells capable of rejection at the outset, as was previously as-
sumed (Alters et al., 1991; Wekerle et al., 2002), and second, 
compensates for this inadequacy by promoting sustained regu-
lation by Foxp3+ T reg cells. An important limitation of adop-
tive transfer studies of this kind is that homeostatic expansion 
of newly transferred cells may lead to false rejection by artifi-
cially magnifying the effect of an otherwise insignificant   
population of effector T cells. A second concern is that the 
lympho-deficient RAG/ recipients developed a wasting 
immunopathology 3–4 wk after transfer of spleen cells devoid 
of Foxp3+ T reg cells (Fig. 2, B and D). As previously stated, 
the onset of systemic immune dysregulation not only shortens 
the time period during which graft experiments can be con-
ducted but also means that graft tolerance cannot be assessed in-
dependently of global immune attack. For these reasons, we 
turned to conventional lymphocyte-replete (CBAxB6hCD2)F1 
mice, which did not develop wasting immunopathology, re-
mained healthy for >150 d, and continued to gain weight 
despite anti-hCD2 mAb treatment, presumably because suffi-
cient T reg cells are spared to prevent autoimmunity yet insuf-
ficient to maintain transplantation tolerance (Fig. 1, A and B). 
Once again, Foxp3+ T reg cells were found to be responsible 
for  maintaining  transplant  tolerance  by  suppressing  effector 
cells (Fig. 3). Indeed, short-term ablation of Foxp3+ cells 50 d 
after the induction of tolerance to a foreign skin graft resulted 
in rejection. In this setting, the rapid destruction of healthy, 
well healed, and well integrated skin dramatically demonstrated 
the rejection potential of residual effector T cells otherwise 
suppressed by Foxp3+ T reg cells (Fig. 3 D).
One critical zone of engagement is the graft tissue itself, 
which has been shown in this study to harbor T cells capable 
of causing its own rejection but which are held in check by 
Foxp3+ iT reg cells. Using a transgenic system in which fe-
male mice have monoclonal CD4 cells recognizing only the 
cognate male peptide, we were able to investigate the role of 
antigen-specific Foxp3+ iT reg cells produced in response to 
antibody-mediated transplant tolerance. De novo, Foxp3+ iT 
reg cells were found in the periphery (and, importantly, not 
the thymus; Fig. 4 B) of those female transgenic mice that had 
accepted a male graft. These generated iT reg cells were shown JEM Vol. 208, No. 10 
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1 mg anti-CD4 (YTS 177.9), anti-CD8 (YTS 105.18), and anti-CD154 (MR1) 
nondepleting mAbs over 7 d. Tolerance of female RAG/ Marilyn.Fox-
p3hCD2 knock-in mice to male B6.RAG1/ skin was achieved using a single 
injection on day 0 of 250 µg anti-CD4 mAb (YTS 177.9; Qin et al., 1990).
YTH655 was prepared in house via purification of integra supernatant. 
An anti–dog rat IgG2b mAb (YKIX 337.217.1) prepared under the same 
conditions was used in all in vivo experiments as an isotype control mAb. 
Unless otherwise stated, Foxp3+hCD2+ T cell ablation was achieved using 
seven daily doses of 250 µg of rat IgG2b anti–human CD2 mAb (YTH655). 
Adoptive cell transfer was achieved by tail vein injection of an appropriate 
volume of washed cell suspension in sterile 1× PBS. 1 mg anti-hCD2 mAb 
(YTH655) or isotype control mAb per mouse was added to the cell suspen-
sion  immediately  before  intravenous  infusion. All  transplant  experiments 
were performed at least twice and results were pooled.
Immunofluorescence analysis and mAbs. Spleen, lymph node, and blood 
cells were labeled directly with fluorescently conjugated mAb. For FACS 
staining, anti-hCD2 (RPA-2.10) PE-conjugated Mouse IgG1, anti–mouse 
CD4 (H129.19) FITC-conjugated mAb, anti-CD3 (145-2C11) PerCp- 
conjugated mAb (BD), anti–mouse CD8 (53–6.7) PE-conjugated mAb, anti–
mouse CD19 (1D3) APC-conjugated mAb, and APC-conjugated anti–mouse 
Foxp3 (JFK-16s) mAb (eBioscience) were used to label live T cells in PBS 
containing 0.1% NaN3, 1% BSA, 5% heat-inactivated normal rabbit serum at 
4°C. When required, the cells were then washed in PBS containing 0.1% 
NaN3 and 0.1% BSA. For Foxp3 intracellular staining, cells were fixed, per-
meabilized, and stained with anti-Foxp3 mAb as per the manufacturer’s proto-
col (eBioscience). Four-color analysis was performed using a FACSCalibur 
(BD) with dual laser (488 nm and 633 nm) excitation. The analysis gate was 
set on the forward and side scatters to eliminate cell debris and dead cells.
In vitro culture of iT reg cells. RAG/ Marilyn.Foxp3hCD2 spleen cells 
were harvested and prepared, including red blood cell lysis, under sterile 
conditions. 5 × 105 RAG/ Marilyn.Foxp3hCD2 cells were cultured at 37°C 
and 6% CO2 in 2 ml R10 medium (RPMI 1640 medium [Lonza] + 10% 
vol/vol FCS [Invitrogen] + 50 µg/ml penicillin + streptomycin [Invitrogen] 
+ 2 mM l-glutamine [Invitrogen] + 50 µM 2-mercapto-ethanol), 2 ng/ml 
TGF-, 1 × 105 B6 WT bone marrow dendritic cells, and 100 nM of male 
H-Y peptide (Dby H-2Ab; NAGFNSNRANSSRSS).
MoFlow cell separation of cultured iT reg cells. All steps were per-
formed using sterile polypropylene materials where relevant to minimize cell 
loss. Cell samples were passed through a 70-µm cell strainer and suspended in 
R-10 medium, centrifuged for 6 min at 1,200 rpm, and resuspended in R-10 
medium. The resultant cell suspension was counted, washed, and 10 µl/150 
million cells of fluorescently conjugated antibodies were added in running 
buffer (1× PBS + 2 mM EDTA + 0.5% wt/vol BSA) before incubation for 
a further 45 min at 4°C. Single stain samples were also prepared for MoFlow 
calibration before cell sorting. After two washes with running buffer, the cell 
suspension was slowly passed through a 70-µm sieve and MoFlow cell sorted 
as per manufacturer’s guidelines.
Online supplemental material. Fig. S1 shows the nature and cellular ex-
pression of the CD52-hCD2 reporter system for Foxp3 expression. Fig. S2 
shows that ablation occurred independently of the host anti-globulin re-
sponse. Fig. S3 shows that transplantation tolerance in mice tolerating grafts 
mismatched for multiple minor antigens was abrogated by ablation of Foxp3+ 
T cells in vivo. Fig. S4 shows induction and isolation of Foxp3+ iTreg in vitro. 
Fig. S5 shows evidence for a small but significant suppressive effect within 
central lymphoid cells derived from tolerant TCR transgenic mice. Fig. S6 
shows that few newly converted Foxp3+ T cells were found in draining 
lymph nodes of mice where hCD2+ (Foxp3+) T cells had failed to suppress 
rejection.  Online  supplemental  material  is  available  at  http://www.jem 
.org/cgi/content/full/jem.20110767/DC1.
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In  a  similar  fashion,  gastrointestinal  mucosal  immunity  is 
tightly regulated at a local level to balance immunity (against 
colonizing pathogens) with tolerance to commensal bacterial 
flora and self-tissue (Coombes et al., 2005). The physiological 
role for induced regulatory T cells still remains unclear. Cer-
tainly  gut  microbiota  seem  to  influence  the  numbers  of 
Foxp3+ T reg cells within intestinal tissue and can safeguard 
against inflammatory bowel disease (Round and Mazmanian, 
2010; Atarashi et al., 2011). It is possible that, unwittingly, our 
short-term therapeutic immune blockade has harnessed this 
otherwise gut-exclusive mechanism to enable exploitation of 
the antiinflammatory activities of iT reg cells in other tissues. 
Decentralizing a substantial part of immune regulation to the 
local tissue in this way perhaps has the advantage of promoting 
a more rapid, efficient, and appropriate immune response to a 
given tissue stress. Microenvironments of immune regulation 
are not restricted to normal healthy tissue, as demonstrated by 
their discovery in many tumor models. Indeed, local amplifica-
tion of tumor-associated regulatory cells may prove a signifi-
cant obstruction to cancer therapy (Colombo and Piconese, 
2007). We would argue that part of the process of generating 
lasting transplant tolerance also involves establishing a local 
tissue microenvironment favoring graft immune regulation. 
Foxp3+ T reg cells are crucial to this process and indeed their 
presence within the demilitarized zone of a tolerated tissue 
may be necessary to keep in check resident T cells otherwise 
capable of insurgency.
Although we have established a crucial role for Foxp3+  
T reg cells, we cannot exclude other regulatory cell subsets 
from playing a part in transplant tolerance. It may be that 
Foxp3+ T reg cells are the dominant suppressors, but in their 
absence and with the right kind of encouragement other regu-
latory mechanisms could fill that void. These findings should 
serve as encouragement for fledgling therapeutic strategies 
aimed at selectively enhancing Foxp3+ T reg cells in transplant 
tolerance. A note of caution though: the persistence of reject-
ing lymphocytes within the graft risks a loss of tolerance if re-
straint  by  Foxp3+ T  reg  cells  is  disrupted  by  subsequent 
life-time events.
MATERIALS AND METHODS
Experimental  mice.  B6.Foxp3hCD2  knock-in,  (CBAxB6hCD2)F1,  (CBA.
RAG1/ × B6.RAG1/), B6.RAG1/, and RAG/ Marilyn.Foxp3hCD2 
knock-in mice were bred and maintained under specific pathogen-free con-
ditions in the animal facility of the Sir William Dunn School of Pathology. 
B6.Foxp3hCD2 reporter mice were generated by homologous recombination 
in a B6-derived ES cell line using a targeting construct in which cDNA en-
coding a human CD2_CD52 fusion protein, along with an intra-ribosomal 
entry site, was inserted into the 3 untranslated region of the endogenous 
foxp3 locus.
Skin grafting, tolerance induction, and ablation of hCD2+ cells. All 
procedures were conducted in accordance with the Home Office Animals   
(Scientific Procedures) Act of 1986. Skin grafting was conducted by grafting full 
thickness tail skin (1 × 1 cm) on the lateral flank as previously described (Qin 
et al., 1990). Grafts were observed daily after the removal of the cast at day 8 and 
considered rejected when no viable donor skin was present. Statistical analysis 
of graft survival was made by the log-rank method. Tolerance across MHC and 
multiple minor histocompatibility barriers was achieved using three doses of   2052 Foxp3+ T reg cells in infectious tolerance | Kendal et al.
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